ATAI News and Press, ATAI Life Sciences N.V. From 11/22/22

The current wave of surging psychedelic research and mainstream popularity has been dubbed the psychedelic renaissance. Decades after they were prohibited, hallucinogenic drugs are revealing astonishing mental-health benefits in clinical trials. Research has shown that even a single dose...

NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study with Massach...

While physicians have worked on developing treatments for physical ailments for centuries, mental health has been neglected for a long time. In recent decades, however, we have become more and more aware of the significant role mental health plays in determining overall health and quality of...

Palm Beach, FL – November 14, 2022 – FinancialNewsMedia.com News Commentary – Anti-anxiety drugs are medications that are used to treat anxiety disorders that are mainly used to relieve anxiety and tension, work by reducing the symptoms of anxiety, such as f...

Atai Life Sciences N.V. (ATAI) Q3 2022 Earnings Conference Call November 10, 2022 08:30 ET Company Participants Stephen Bardin - Chief Financial Officer Florian Brand - Chief Executive Officer and Co-Founder Srini Rao - Chief Scientific Officer and Co-Founder ...

Clinical-stage biopharmaceutical company atai Life Sciences (Nasdaq: ATAI) reported financial results for the third quarter ending Sept. 30, providing updates on its clinical trials looking at the treatment of depression using ketamine – particularly an at-home therapy for ...

ATAI Life Sciences press release ( NASDAQ: ATAI ): Q3 GAAP EPS of -$0.22 beats by $0.01 . In Q3, ATAI continued to advance its programs and is looking forward to additional clinical milestones for the remainder of 2022 and beyond. As of now, eight compounds are in ...

Last patient dosed in the Phase 2a proof-of-concept trial of PCN-101 (R-ketamine) for treatment-resistant depression (TRD), with topline results expected around year-end 2022. Announced positive preliminary pharmacokinetics and pharmacodynamics results in a Phase 1 study of GR...

ATAI Life Sciences ( NASDAQ: ATAI ) is scheduled to announce Q3 earnings results on Thursday, November 10th, before market open. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $0M. Over the last 3 months, EPS estimates have seen 2 upward r...

Edward J. Delaney, an American author who’s written fictional books such as “Follow the Sun” and “Warp and Weft,” recently published a new novel based on the life of Cary Grant. The novel in question, “ The Acrobat ,” focuses on Grant’...